Genomic Classification of HER2-Positive Patients With 80-Gene and 70-Gene Signatures Identifies Diversity in Clinical Outcomes With HER2-Targeted Neoadjuvant Therapy.
Pat W WhitworthPeter D BeitschMary K MurrayPaul D RichardsAngela MislowskyCarrie L DulJames V PellicanePaul L BaronRakhshanda Layeequr RahmanLaura A LeeBeth B DupreePond R KelemenAndrew Y AshikariRaye J BudwayCristina Lopez-PenalverWilliam C DooleyShiyu WangPatricia DauerAndrea R MenicucciErin B YoderChristine FinnLisa E BlumencranzM William AudehPublished in: JCO precision oncology (2022)
The 80-gene assay identified meaningful genomic diversity in patients with cHER2 disease. Patients with cHER2/gHER2 tumors, who benefitted most from dual HER2-targeted therapy, accounted for approximately half of the cHER2 cohort. Genomically Luminal tumors had low pCR rates but good 5-year outcomes. cHER2/gBasal tumors derived no benefit from dual therapy and had significantly worse 5-year prognosis; these patients merit special consideration in future trials.
Keyphrases
- copy number
- genome wide
- end stage renal disease
- genome wide identification
- newly diagnosed
- ejection fraction
- dna methylation
- chronic kidney disease
- machine learning
- rectal cancer
- locally advanced
- type diabetes
- squamous cell carcinoma
- gene expression
- high throughput
- stem cells
- adipose tissue
- skeletal muscle
- mesenchymal stem cells
- current status
- patient reported outcomes
- genome wide analysis
- real time pcr